Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
February 01, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to...
January 28, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
January 27, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Files Application to list to the NASDAQ

DENVER, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
January 22, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
January 11, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
January 07, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Shares Intellectual Property Update

Company files seven provisional patent applications with United States Patent and Trademark Office DENVER, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF)...
January 05, 2021 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
December 21, 2020 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...
December 15, 2020 07:30 ET | Source: Mydecine Innovations Group Inc.

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right